Nomio has secured $4 million in fresh funding, led by Collaborative Fund, as it scales from a niche performance product used by elite athletes into a broader commercial offering. The Stockholm-based startup is pioneering a new category within sports nutrition by commercializing Isothiocyanates (ITCs)—a bioactive compound derived from broccoli sprouts—positioning itself at the intersection of biotechnology and high-performance wellness.
Unlike traditional performance shots that rely on caffeine or nitrates, Nomio’s formulation is built around cellular resilience and recovery. Its core innovation lies in stabilizing ITCs, which have been shown to help the body manage lactic acid buildup during intense exercise, reduce oxidative stress by activating the Nrf2 pathway, and accelerate recovery metrics such as muscle soreness and heart rate variability. This “science-first” approach allows Nomio to differentiate itself as a technical performance tool rather than a generic wellness drink.
The brand’s early traction has been driven by organic adoption among elite athletes, including Cole Hocker and Andreas Almgren, as well as professional cycling teams where marginal gains in recovery can significantly impact performance. This grassroots credibility has helped Nomio build a strong foundation without heavy marketing spend, reinforcing its positioning as a performance-driven, athlete-validated product.
Nomio’s rise also aligns with the broader boom in hyper-functional wellness shots, a category expected to reach $1.5 billion globally by 2027. As competitors focus on energy, immunity, or productivity, Nomio is carving out a distinct niche in endurance and recovery optimization, targeting serious athletes rather than mass-market consumers—at least in its current phase.
From a strategic standpoint, the company’s biggest advantage lies in its proprietary stabilization process for ITCs, which creates a meaningful barrier to entry in a crowded supplement market. By owning the underlying science and extraction technology, Nomio is effectively building an IP-driven moat, similar to how performance brands differentiate through proprietary materials or formulations.
With this funding, Nomio is expected to expand beyond the Nordic region into key markets like the US and UK, moving from an “insider secret” to a mainstream performance product. If successful, it could redefine how athletes—and eventually everyday consumers—approach recovery, shifting the focus from stimulants to cellular-level optimization.
